Some of the top neurology startups in Korea are getting a lot of attention due to their amazing work in neuroscience. The study of the human brain is complex which is why technology is vital to help us understand what is going on inside this organ. There has been a lot of focus in regards to the study of Alzheimer’s as it is becoming a concern in Korea due to the country’s aging population. It is a fact that cognitive decline increases with age and in Korea, it is estimated that over 3 million elderly people will be diagnosed with Alzheimer’s disease by 2050. Thankfully there are many medical startups focusing on neurology to fight illnesses like Alzheimer’s and Autism.
One of the top RNA therapeutics startups in Korea is BioOrchestra. They focus on neurodegenerative diseases such as Alzheimer’s disease using its RNA-based drug and drug delivery platform. Therefore, they use a fully integrated platform for drug development. BioOrchestra was able to raise $45 million for their Series C round.
SoVarGen is a biotech startup in Korea that develops a pipeline of product candidates in the area of brain diseases such as Alzheimer’s disease, brain tumors, and intractable epilepsy. They have raised over $30 million for their Series B funding.
Astrogen is a Korean biotech startup that develops new drugs for intractable neurological diseases. They are carrying out Phase 2 clinical trials for its autism spectrum disorder treatment. In addition, they plan to carry out Phase 1 clinical trials for Alzheimer’s disease treatment. Astrogen recently partnered with a French company that specializes in AI for drug design. They will collaborate to discover and develop small molecule pre-clinical drug candidates for Parkinson’s disease. Astrogen has raised over $13 million in funding to date.
Furthermore, Neurophet was able to secure $5 million in series A.
Korean therapeutics startup Nunap develops and tests its software-based treatments for neurological disorders. They are currently building out their platform while developing their first product called Nunap Vision. It is a VR headset that helps with perception training. This technology aims to help treat visual field defects that are caused by brain damage, such as strokes. They have raised over $4.2 million from Korean VC firms such as Company K Partners and K2 Investment Partners just to name a few. The Ministry of Food and Drug Safety approved Nunap’s clinical trial of Nunap Vision.
Furthermore, they were able to do their clinical trials at Asan Medical Center, Seoul National University Hospital, Seoul National University Bundang Hospital, and Samsung Medical Center.
“The approval of the new clinical trial will become the first step in securing the local market dominance for digital therapy,” said the CEO of Nunaps, Kwang Dong-hwa.
SEVENPOINTONE is the developer of a digital healthcare platform designed to provide dementia diagnosis algorithms. They offer a VR-based healthcare diagnostic solution that provides an assessment of early signs or symptoms associated with dementia. Moreover, it can also be used for the development of mental and cognitive skills, enabling elderly people and dementia patients with brain-enhancing content that helps to cope with dementia side effects.
BRILS, an Incheon-based robot automation specialist founded in 2015, is currently preparing for its 2025…
The Heart of Seoul Leisure In early 2026, the Seoul Metropolitan Government and local residents…
The Ministry of SMEs and Startups finalized a 16.5 trillion won budget through the National…
CT5 secured the Best of Innovation Award at CES 2026 in Las Vegas this January.…
The Demand for Absolute Stillness In February 2026, the South Korean theater industry faces a…
Since the 1990s, three native Korean software powerhouses—Hancom Office, ALTools, and V3—have maintained a firm…